FGFR1 overexpression	Urothelial Cancer	FGFR1 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR1 overexpression	Renal Cell Carcinoma	FGFR1 overexpression	Renal Cell Carcinoma	sorafenib Resistant: C3 – Early Trials sorafenib Resistant : C3	sorafenib Resistant: C3 – Early Trials sorafenib Resistant : C3
FGFR1 overexpression	Lung Cancer	FGFR1 overexpression	Lung Cancer	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3	ponatinib Resistant: C3 – Early Trials ponatinib Resistant : C3
FGFR1 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR1 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR1 overexpression	Urothelial Cancer	FGFR1 overexpression	Urothelial Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR1 overexpression	Hormone Receptor Positive Breast Cancer	FGFR1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR1 overexpression	Non Small Cell Lung Cancer	FGFR1 overexpression	Non Small Cell Lung Cancer	M6123 Sensitive: D – Preclinical M6123 Sensitive : D	M6123 Sensitive: D – Preclinical M6123 Sensitive : D
FGFR1 overexpression	HER2 Negative Breast Cancer	FGFR1 overexpression	HER2 Negative Breast Cancer	alpelisib Resistant: D – Preclinical alpelisib Resistant : D	alpelisib Resistant: D – Preclinical alpelisib Resistant : D
FGFR1 overexpression	Hepatocellular Cancer	FGFR1 overexpression	Hepatocellular Cancer	lenvatinib Resistant: D – Preclinical lenvatinib Resistant : D	lenvatinib Resistant: D – Preclinical lenvatinib Resistant : D
FGFR1 overexpression	Liposarcoma	FGFR1 overexpression	Liposarcoma	erdafitinib Resistant: D – Preclinical erdafitinib Resistant : D	erdafitinib Resistant: D – Preclinical erdafitinib Resistant : D
FGFR1 overexpression	Gastric Cancer	FGFR1 overexpression	Gastric Cancer	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR1 overexpression	Non Small Cell Lung Cancer	FGFR1 overexpression	Non Small Cell Lung Cancer	anlotinib Sensitive: D – Preclinical anlotinib Sensitive : D	anlotinib Sensitive: D – Preclinical anlotinib Sensitive : D

FGFR1 overexpression

Associations